3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
1
Mesothelioma
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Leukemia
1
Carcinoma, Non-Small-Cell Lung
1
Adrenocortical Carcinoma
1
Interventions
venetoclax
6
Azacitidine
6
Cytarabine
5
fludarabine
4
Methotrexate
3
fludarabine phosphate
2
aldesleukin
2
RO6839921
2
Mitoxantrone
2
Interleukin-2
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Decitabine
2
Dasatinib
2
zileuton
1
thymoglobulin
1
spartalizumab
1
sabatolimab
1
quizartinib
1
pulrodemstat besilate
1
posaconazole
1
plerixafor
1
gilteritinib
1
etoposide phosphate
1
emvododstat
1
daratumumab
1
blinatumomab
1
Sorafenib
1
Sirolimus
1
Panobinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia, Myeloid
×
IPI-549
×
Clear all
NCT07439211
2026-03-03
GAVEL
Dana-Farber Cancer Institute
Phase 1
Not yet recruiting
48 enrolled